Oliver Freudenreich is a Psychiatry physician affiliated with Harvard University. OpenAlex indexes 387 publications with 8,946 citations (h-index 52); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Lin Psychiatry Associates Inpatient Consult
Boston, MA 021142696
Telephone
617-912-7800Registry record last updated 3 Jan 2013.
Clinical trials
- Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study
Sponsor: North Suffolk Mental Health Association
- Risperidone Augmentation in Patients With Schizophrenia
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Pharmaceuticals, IncProgram year20212 payments
- Neurocrine Biosciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
89.1%Atypical Antipsychotic67%Clozapine60%Aripiprazole24%Olanzapine16%Part D<11 patientsBenzodiazepine9.6%Clonazepam100%Part D<11 patients+ 2 more classes in this area
Respiratory
5.7%Anticholinergic5.7%Glycopyrrolate100%Part D<11 patientsMetabolism & gastrointestinal
5.2%Biguanide (metformin)5.2%Metformin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Consensus statement on the use of clozapine during the COVID-19 pandemic
Journal of Psychiatry and Neuroscience
2020 - Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice
The Journal of Clinical Psychiatry
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”